Company profile PRQR

ProQR Therapeutics N.V
proqr therapeutics is a leiden, nl based biotech company focused on developments of drugs to treat genetic disorders. based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. founded by industry icons and based on ground breaking science we strive to make a meaningful impact. check out our website for vacancies: w...ww.proqr.com Show More
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics -stock -company to provide analysis

Correlation between past revenue and ProQR Therapeutics -stock -company search interest

There is not enough data for ProQR Therapeutics -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics login to provide analysis

Correlation between past revenue and ProQR Therapeutics login search interest

There is not enough data for ProQR Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 09:53:17.

After 39 days of this quarter the interest is at 73.0. Based on that we can calculate that during remaining 52 days it will total up to 170.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019159
77
-51.6% QoQ
138
79.2% QoQ
217
57.2% QoQ
2020 46
-71.1% YoY -78.8% QoQ
220
185.7% YoY 378.3% QoQ
44
-68.1% YoY -80.0% QoQ
33
-84.8% YoY -25.0% QoQ
2021 222
382.6% YoY 572.7% QoQ
286
30.0% YoY 28.8% QoQ
55
25.0% YoY -80.8% QoQ
358
984.8% YoY 550.9% QoQ
2022 165
-25.7% YoY -53.9% QoQ
0
-100.0% YoY -100.0% QoQ
53
-3.6% YoY inf% QoQ
77
-78.5% YoY 45.3% QoQ
2023 124
-24.8% YoY 61.0% QoQ
0
-24.8% YoY -100.0% QoQ
46
-13.2% YoY inf% QoQ
167
116.9% YoY 263.0% QoQ
2024 73
-41.1% YoY -56.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ProQR Therapeutics news search interestLast update: February 09 2024 09:53:16.
Correlation coefficient between keyword and revenue is -1.0
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 09:53:19.

The average 5 years interest of ProQR Therapeutics news was 9.81 per week.
The last year interest of ProQR Therapeutics news compared to the last 5 years has changed by -19.67%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -35.67%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics pipeline to provide analysis

Correlation between past revenue and ProQR Therapeutics pipeline search interest

There is not enough data for ProQR Therapeutics pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics AX-0810 to provide analysis

Correlation between past revenue and ProQR Therapeutics AX-0810 search interest

There is not enough data for ProQR Therapeutics AX-0810 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics AX-0810 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics AX-1412 to provide analysis

Correlation between past revenue and ProQR Therapeutics AX-1412 search interest

There is not enough data for ProQR Therapeutics AX-1412 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics AX-1412 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics AX-1005 to provide analysis

Correlation between past revenue and ProQR Therapeutics AX-1005 search interest

There is not enough data for ProQR Therapeutics AX-1005 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics AX-1005 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics AX-2911 to provide analysis

Correlation between past revenue and ProQR Therapeutics AX-2911 search interest

There is not enough data for ProQR Therapeutics AX-2911 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics AX-2911 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ProQR Therapeutics Axiomer RNA-editing to provide analysis

Correlation between past revenue and ProQR Therapeutics Axiomer RNA-editing search interest

There is not enough data for ProQR Therapeutics Axiomer RNA-editing to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ProQR Therapeutics Axiomer RNA-editing to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PRQR
Earnings date: 2024-02-28 After close
Company name: ProQR Therapeutics N.V
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T11:00:00Z

GlobeNewswire
ProQR Announces First Quarter 2026 Operating and Financial Results

2026-05-11T12:00:00Z

GlobeNewswire
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomerâ„¢ RNA Editing Platform

2026-05-04T12:00:00Z

GlobeNewswire
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

2026-04-30T12:00:00Z

GlobeNewswire
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

2026-04-08T20:00:00Z

GlobeNewswire
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

2026-04-08T12:00:00Z

GlobeNewswire
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

2026-03-25T12:00:00Z

GlobeNewswire
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

2026-03-09T12:00:00Z

GlobeNewswire
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

2026-03-03T21:30:00Z

GlobeNewswire
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

2026-02-09T13:00:00Z

GlobeNewswire
ProQR Announces Planned Changes to Board Composition

2026-01-08T13:00:00Z

GlobeNewswire
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

2025-12-01T13:00:00Z

GlobeNewswire
ProQR to Participate in 8th Annual Evercore Healthcare Conference

2025-11-06T12:00:00Z

GlobeNewswire
ProQR Announces Third Quarter 2025 Operating and Financial Results

2025-11-04T13:26:26Z

Analyst Upgrades
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

2025-10-20T08:08:20-04:00

SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - ProQR Therapeutics N.V. (0001612940) (Filer)